From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology
Open Access
- 27 September 2025
- journal article
- research article
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (6) , 907-915
Abstract
The advent of comprehensive genomic sequencing has catalysed the emergence of paediatric precision medicine platforms globally. These have established the feasibility of profiling tumours at scale, enhancing our understanding of the genetic landscape of paediatric tumours and enabling identification of driver mutations and actionable targets. In turn, this has created the opportunity for development of novel precision-guided therapies (PGT). This commentary synthesizes evidence from major collaborative trials with a focus on outcome reporting, particularly in the relapsed/refractory and high-risk patient cohorts. Patients receiving PGT in these cohorts demonstrate meaningful responses and survival benefit, particularly when treatment is based on high-level clinical evidence and administered early in the disease course. However, challenges remain in addressing low uptake of PGT, likely hindered by substantial barriers in access and complex pharmaceutical regulatory constraints. Furthermore, heterogeneity in recommendation and outcome reporting hinders data harmonisation and generalisability of results. In addition to improving outcomes, comprehensive profiling can contribute to diagnostic refinement and identification of germline variant detection in a subset of patients. Emerging studies, conducted through national initiatives, signify the potential benefit of precision medicine for all patients with childhood cancer regardless of risk. A dynamic approach to address challenges and ensure cost–benefit is necessary to embed precision oncology as a standard of care for all children with cancer.Keywords
Funding Information
- National Health and Medical Research Council (APP2019056, APP2017898, APP2018642)
- Cancer Institute NSW (TPG2037, 2021/TPG2112)
- Zero Childhood Cancer Program
- University of New South Wales
This publication has 53 references indexed in Scilit:
- Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunitiesPediatric Blood & Cancer, 2024
- Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryEuropean Journal of Cancer, 2022
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated TumorJAMA Oncology, 2021
- The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017The Lancet Oncology, 2019
- The landscape of genomic alterations across childhood cancersNature, 2018
- Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumoursNature, 2018
- Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumorsPediatric Blood & Cancer, 2016
- Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot studyEuropean Journal of Cancer, 2016
- Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid TumorsJAMA Oncology, 2016
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthJAMA, 2015